Biological
mRNA-1647 cytomegalovirus vaccine clinical trials
Also written mRNA-1647.
- studies test it
- 9
- open now
- 0
- in phase 3
- 1
- first study started
- 2017
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
9 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 5
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
2019-nCoV Vaccine mRNA-1273 (1) · mRNA-1010 influenza vaccine (1) · mRNA-1345 respiratory syncytial virus vaccine (1) · MRNA-1443 (1)
Studies
Open first, then newest update. How each study uses mRNA-1647 cytomegalovirus vaccine is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.Active, not recruitingPhase 2ModernaTX, Inc.NCT05683457Written as mRNA-1647
- A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of AgeCompletedPhase 1/2ModernaTX, Inc.NCT05575492Written as mRNA-1647
- Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy AdultsCompletedPhase 2ModernaTX, Inc.NCT04232280Written as mRNA-1647
- A Study of Modified mRNA Vaccines in Healthy AdultsCompletedPhase 1ModernaTX, Inc.NCT05397223Written as mRNA-1647
- A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 VaccineCompletedPhase 2ModernaTX, Inc.NCT04975893Written as mRNA-1647
- A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of AgeTerminatedPhase 3ModernaTX, Inc.NCT05085366Written as mRNA-1647
- A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and RecipientsWithdrawnPhase 2ModernaTX, Inc.NCT06133010Written as mRNA-1647
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647CompletedPhase 1ModernaTX, Inc.NCT05105048Written as mRNA-1647
- Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy AdultsCompletedPhase 1ModernaTX, Inc.NCT03382405Written as mRNA-1647
Codes
What other systems call mRNA-1647 cytomegalovirus vaccine · ClinicalTrials.gg INT001889
- MeSH (NLM) C000722750mRNA-1647 cytomegalovirus vaccineOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722750 | mRNA-1647 cytomegalovirus vaccine | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.